ALSO NOTED: Prana chief steps down; Erbitux trial shows added survival time; Encysive makes bid in Europe; and much more...

> Chutes & Ladders: Prana Biotechnology says that CEO Jonas Alsenas has stepped down. Story

> Germany's Merck says that a Phase I/II trial of Erbitux shows the cancer drug may add to the survival time of patients whose cancer had spread beyond their bowels and was beyond surgery when added to standard chemotherapy. Story

> Encysive Pharmaceuticals has made a bid to market its pulmonary arterial hypertension drug Thelin in Europe. Story

> The FDA has given Hoffman-LaRoche approval to use Xeloda for use following colon cancer research. The developer filed for the new indication in August of last year. Story

> San Diego-based Kalypsys and NovImmune have struck a collaboration agreement. Release

> India's Aurobindo has received FDA approval for its AIDS drug Lamivudine. Story

> Cerner is acquiring software-maker Bridge Medical for $11 million. Story

And Finally... Medicare may be planning a big formulary, but some seniors switching from Medicaid to Medicare may find themselves without coverage for badly needed drugs. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.